HomeComparePKBO vs XYLD

PKBO vs XYLD: Dividend Comparison 2026

PKBO yields 8888.89% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PKBO wins by $17290949737713800.00M in total portfolio value
10 years
PKBO
PKBO
● Live price
8888.89%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17290949737713800.00M
Annual income
$16,916,578,202,775,594,000,000.00
Full PKBO calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — PKBO vs XYLD

📍 PKBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPKBOXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PKBO + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PKBO pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PKBO
Annual income on $10K today (after 15% tax)
$755,555.56/yr
After 10yr DRIP, annual income (after tax)
$14,379,091,472,359,256,000,000.00/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, PKBO beats the other by $14,379,091,472,359,256,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PKBO + XYLD for your $10,000?

PKBO: 50%XYLD: 50%
100% XYLD50/50100% PKBO
Portfolio after 10yr
$8645474868856900.00M
Annual income
$8,458,289,101,387,797,000,000.00/yr
Blended yield
97.83%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PKBO buys
0
XYLD buys
0
No recent congressional trades found for PKBO or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPKBOXYLD
Forward yield8888.89%10.98%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$17290949737713800.00M$25.3K
Annual income after 10y$16,916,578,202,775,594,000,000.00$3,219.02
Total dividends collected$17265985963886318.00M$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: PKBO vs XYLD ($10,000, DRIP)

YearPKBO PortfolioPKBO Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$899,589$888,888.89$10,818$1,098.39+$888.8KPKBO
2$75,694,763$74,732,202.61$11,738$1,222.51+$75.68MPKBO
3$5,957,858,933$5,876,865,536.53$12,774$1,364.64+$5957.85MPKBO
4$438,676,028,838$432,301,119,780.33$13,944$1,527.86+$438676.01MPKBO
5$30,217,280,421,144$29,747,897,070,286.80$15,270$1,715.87+$30217280.41MPKBO
6$1,947,399,451,993,550$1,915,066,961,942,926.00$16,775$1,933.09+$1947399451.98MPKBO
7$117,429,004,658,116,600$115,345,287,244,483,520.00$18,490$2,184.87+$117429004658.10MPKBO
8$6,625,994,131,926,989,000$6,500,345,096,942,805,000.00$20,450$2,477.63+$6625994131926.97MPKBO
9$349,879,939,194,586,330,000$342,790,125,473,424,500,000.00$22,697$2,819.19+$349879939194586.31MPKBO
10$17,290,949,737,713,800,000,000$16,916,578,202,775,594,000,000.00$25,280$3,219.02+$17290949737713800.00MPKBO

PKBO vs XYLD: Complete Analysis 2026

PKBOStock

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Full PKBO Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this PKBO vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PKBO vs SCHDPKBO vs JEPIPKBO vs OPKBO vs KOPKBO vs MAINPKBO vs QYLDPKBO vs JEPQPKBO vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.